3D-BrAIn Revolutionary high-resolution human 3D brain organoid platform integrating AI-based analytics
- Coordinator
- Erasmus Universitair Medisch Centrum Rotterdam, Netherlands
- Runs
- 1 April 2023 to 31 March 2028
- Status
- Running
- EU funding
- €2.0m
- Total cost
- €2.0m
- Partners
- 4 organisations in 4 countries
- Type
- European Innovation Council
- Grant agreement
- 101098791
What the project is doing
In the project's own words, from its summary on CORDIS.
The long-term vision of the 3D-BrAIn consortium is to revolutionize personalized precision medicine for central nervous system (CNS)disorders, by developing an innovative bio-digital twin model of the human brain that is personalized, precise, and predictive. In this pathfinder project we bring together three breakthrough technologies: 1) a novel, highly reproducible human brain modellingtechnology using robust adherent iPSC-derived 3D cortical organoid cultures, 2) a unique, state-of-the-art 3D multi-electrode array(MEA) technology for non-invasive high-resolution electrophysiological recordings and 3) a novel approach to analyse and interpretthe large quantities of functional data using tailored automated machine learning (ML)-based algorithms.
With this breakthrough approach we overcome significant hurdles that made it thus far impossible to create a truly representativeand functional model of the CNS for personalized medicine, drug screening and neurotoxicity testing. The revolutionary 3D-BrAInhigh-precision CNS platform will allow robust and accurate modelling of the CNS for a broad range of neuropsychiatric diseases. Ultimately, the 3D-BrAIn technology will be translatable to multiple other organ systems (cardiomyocytes, pancreatic islets, retina), tonon-invasively obtain longitudinal 3D high-resolution electrophysiological recordings and effectively interpret them.
In this project a prototype of the 3D-BrAIn platform will be developed by growing functional 3D organoids that faithfully resemblethe human cortex on 3D MEA micropillar electrodes, enabling continuous functional monitoring and by developing ML-basedalgorithms that can process and interpret the large spatiotemporal data sets. Once all individual components are optimized andintegrated, proof-of-concept will be obtained by validating the platform for two of the envisaged applications: CNS drugdevelopment and neurotoxicity screening.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Erasmus Universitair Medisch Centrum Rotterdam | Rotterdam | Netherlands | Coordinator |
| 3brain AG | Pfaffikon | Switzerland | Associatedpartner |
| Ludwig-Maximilians-Universitaet Muenchen | Planegg | Germany | Participant |
| Universita Degli Studi Di Genova | Genova | Italy | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI